Breaking Finance News

Johnson & Johnson (NYSE:JNJ) stock price target increased to $140.00, issued a research note today by Jefferies & Co

In a report released on 06/16/2017 Jefferies & Co increased the stock price target of Johnson & Johnson (NYSE:JNJ) to $140.00 indicating a possible upside of 0.04%.

Previously on 5/29/2017, Vetr Inc. reported on Johnson & Johnson (NYSE:JNJ) increased the target price from $0.00 to $132.33. At the time, this indicated a possible upside of 0.04%.

Yesterday Johnson & Johnson (NYSE:JNJ) traded -0.27% lower at $134.35. The company’s 50-day moving average is $132.79 and its 200-day moving average is $129.43. The last closing price is up 1.51% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 4,334,763 shares of the stock traded hands, down from an average trading volume of 5,349,390

See Chart Below

Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08 with a P/E ratio of 22.23 The company’s market cap is currently $0.

In addition to Jefferies & Co reporting its stock price target, a total of 18 brokers have issued a research note on the company. The average stock price target is $117.44 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.